News

Video

ASCRS 2024: 10-year results of using two iStents with cataract surgery

Paul Harasymowycz, MD, details his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma" from this year's ASCRS meeting in Boston, Massachusetts.

At this year's ASCRS meeting in Boston, Massachusetts, we caught up with Paul Harasymowycz, MD, who detailed his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma." Here, he shares the highlights from a decade's worth of data.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Paul Harasymowycz, MD:

Hello, I'm Dr Paul Harasymowycz, from University of Montreal and McGill University. Today we have the pleasure of presenting our 10-year results of using two [first-generation trabecular micro bypass] iStents with cataract surgery. So that's a decade of results using MIGS surgery. I think that's a very important contribution to our knowledge.

This was a real world study. In the end, we had 56 patients that we followed over time. The most important is that they had OCT stability up until 10 years. The average pressure before was higher than 18. And even after 10 years, a decade, their pressure was almost at 14. That's very important. Another finding in our study was that 75% of our patients, their pressure was below 15. And we know, usually, the lower we keep the pressure, the less likelihood is that their glaucoma will progress. And so I think that's great for our patients. In the end, it's all about the patients. And the study does show that using angle surgery may be beneficial to your patients as well.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.